Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia: Part I. In vivo studies

Leukemia Research

Volumn 28, Issue 11, 2004, Pages 1125-1136

  Malek, Karim ^a   Boosalis, Michael S ^a   Waraska, Kristin ^a   Mitchell, Beverly S ^b   Wright, Daniel G ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

acute myelogenous leukemia; AML; bcr abl positive leukemia; chronic myelogenous leukemia; chronic myelogenous leukemia in blast crisis; CML; CML blast crisis; CML BC; IMPDH; inosine monophosphate dehydrogenase; Ph' chromosome; Philadelphia chromosome

Indexed keywords

BCR ABL PROTEIN; INOSINE PHOSPHATE; OXIDOREDUCTASE; TIAZOFURIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW CELL; CIRCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HEMATOLOGY; HUMAN; HUMAN CELL; INFUSION; LEUKEMIA CELL; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FEMALE; GENES, ABL; HUMANS; IMP DEHYDROGENASE; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME;

EID: 4544366831     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.03.003     Document Type: Article

References (38)

1. Cortes J., Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin. Hematol. 40:2003;79-86
2. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. International STI571 CML Study Group Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346:2002;645-652
3. Garcia-Manero G., Faderl S., O'Brien S., Cortes J., Talpaz M., Kantarjian H.M. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 98:2003;437-457
4. Gharehbaghi K., Burgess G.S., Collart F.R., Litz-Jackson S., Huberman E., Jayaram H.N., et al. p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene. Leukemia. 8:1994;1257-1263
5. Robins R.K., Srivastava V.L., Narayanan L., Plowman L., Pauli K.D. 2-Beta-D-ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastases. J. Med. Chem. 25:1982;107-108
6. Jayaram H.N., Ahluwalia G.S., Dion R.L., Gebeyehu G., Marquez V.E., Kelley J.A., et al. Conversion of 2-beta-D-ribofuranosylselenazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Biochem. Pharmacol. 32:1983;2633-2636
7. O'Dwyer P.J., Shoemacher D.D., Jarayam H.N., et al. Tiazofurin a new anti-tumor agent. Invest. New Drugs. 2:1984;79-84
8. Balis F.M., Lange B.L., Packer R.J., et al. Pediatric phase I trial and pharmacokinetics of Tiazofurin (NSC 286193). Cancer Res. 45:1985;5169-5172
9. Dorr RT, Von Hoff DD, editors. "Tiazofurin," cancer chemotherapy handbook. 2nd ed. East Norwalk, CT: Appleton and Lange; 1994. p. 911-4.
10. Jayaram H.N., Pillwein K., Nichols C.R., Hoffman R., Weber G. Selective sensitivity to Tiazofurin of human leukemic cells. Biochem. Pharmacol. 35:1986;2029-2032
11. Tricot G., Weber G. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5′-phosphate dehydrogenase activity. Anticancer Res. 16:1996;3341-3347
12. Tricot G.J., Jarayam H.N., Nichols C.R., Pennington K., Lapis E., Weber G., et al. Hematologic and biochemical action of Tiazofurin (NSC 286193) in a case of refractory acute myeloid leukemia. Cancer Res. 47:1987;4988-4991
13. Tricot G.J., Jarayam H.N., Lapis E., Natsumeda Y., Nichols C.R., Kneebone P., et al. Biochemically directed therapy of leukemia with Tiazofurin, a selective blocker of inosine 5′-monophosphate dehydrogenase activity. Cancer Res. 49:1989;3696-3701
14. Dr. J Mel Sorensen, Investigational Drug Branch, CTEP, DCT, NCI, personal communication.
15. Lucas D.L., Webster H.K., Wright D.G. Purine metabolism in myeloid precursor cells during maturation: studies with the HL-60 cell line. J. Clin. Invest. 72:1983;1889-1900
16. Lucas D.L., Robins R.K., Knight R.D., Wright D.G. Induced maturation of the human promyelocytic leukemia cell line, HL-60, by 2-beta-D- ribofuranosylselenazole-4-carboxamide. Biochem. Biophys. Res. Commun. 115:1983;971-980
17. Wright D.G. A role for guanine ribonucleotides in the regulation of myeloid cell maturation. Blood. 69:1987;334-338
18. Knight R.D., Mangum J., Lucas D.L., Cooney D.A., Khan E.C., Wright D.G. Inosine monophosphate dehydrogenase and myeloid cell development. Blood. 69:1987;634-639
19. Sokoloski J.A., Blair O.C., Sartorelli A.C. Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5′-phosphate dehydrogenase. Cancer Res. 46:1986;2314-2319
20. Yu J., Lemas V., Page J.D., Connor J.D., Yu A.L. Induction of erythroid differentiation in K562 cells by inhibitors of inosine monophosphate dehydrogenase. Cancer Res. 49:1988;5555-5560
21. Olah E., Natsumeda Y., Ikegami T., Kote Z., Horanyi M., Szelenyi J., et al. Induction of erythroid differentiation and modulation of gene expression by Tiazofurin in K-562 leukemia cells. Proc. Natl. Acad. Sci. U.S.A. 85:1988;6533-6537
22. Kharbanda S.M., Sherman M.L., Spriggs D.R., Kufe D.W. Effects of Tiazofurin on protooncogene expression during HL-60 cell differentiation. Cancer Res. 48:1988;5965-5968
23. Kiguchi K., Collart F.R., Henning-Chubb C., Huberman E. Cell differentiation and altered IMP dehydrogenase expression induced in human T-lymphoblastoid leukemia cells by mycophenolic acid and Tiazofurin. Exp. Cell Res. 187:1990;47-53
24. Goldstein B.M., Leary J.F., Farley B.A., Marquez V.E., Levy P.C., Rowley P.T. Induction of HL60 cell differentiation by Tiazofurin and its analogues: characterization and efficacy. Blood. 78:1991;593-598
25. URL for common toxicity criteria. http://ctep.info.nih.gov/ctc3/ctc.htm.
26. Boyum A. Isolation of mononuclear cells and granulocytes from human peripheral blood. Scand. J. Clin. Lab. Invest. 21(Suppl. 97):1968;77-89
27. Balzarini J., De Clercq E. Assay method for monitoring the inhibitory effects of antimetabolites on the activity of inosinate dehydrogenase in intact human CEM lymphocytes. Biochem. J. 287:1992;785-790
28. Glesne D.A., Collart F.R., Huberman E. Regulation of IMP dehydrogenase gene expression by its end products, guanine ribonucleotides. Mol. Cell Biol. 11:1991;5417-5425
29. Konno Y., Natsumeda Y., Nagai M., Yamaji Y., Ohno S., Suzuki K., et al. Expression of human IMP dehydrogenase types I and II in Escherichia coli and distribution in human normal lymphocytes and leukemic cell lines. J. Biol. Chem. 266:1991;506-509
30. Nagai M., Natsumeda Y., Konno Y., Hoffman R., Irino S., Weber G Selective up-regulation of type II inosine 5′-monophosphate dehydrogenase messenger RNA expression in human leukemias. Cancer Res. 51:1991;3886-3890
31. Tallman M.S., Nabhan C., Feusner J.H., Rowe J.M. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 99:2002;759-767
32. Morris R.E., Hoyt E.G., Murphy M.P., Eugui E.M., Allison A.C. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transpl. Proc. 22:1990;1659-1662
33. Platz K.P., Bechstein W.O., Eckhoff D., Suzuki Y., Sollinger H.W. RS-61443 reverses acute allograft rejection in dogs. Surgery. 110:1991;736-740
34. Sollinger H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 60:1995;225-232
35. Talpaz M., Goldman J.M., Sawyers C.L., Hochhaus A., Silver R.T., Smith B.D., et al. International STI571 Study Group High dose Imatinib (STI571, Gleevec) provides durable long-term outcomes for patients with chronic myeloid leukemia (CML) in accelerated phase (AP) or myeloid blast crisis (BC): follow-up of the phase-II studies. Blood. 102(11):2003;905a
36. Harrison S.D., O'Dwyer P.J., Trades M.W. Therapeutic synergism of Tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice. Cancer Res. 46:1986;3396-3400
37. Taniki T., Prajda N., Monden Y., Weber G. Synergistic action of taxol and Tiazofurin in human ovarian, pancreatic and lung carcinoma cells. Cancer Biochem. Biophys. 13:1993;295-302
38. Yeh Y.A., Olah E., Wendel J.J., Sledge G.W. Jr., Weber G. Synergistic action of taxol with Tiazofurin and methotrexate in human breast cancer cells: schedule-dependence. Life Sci. 54:1994;431-435